Although conventional anti-HER2 therapy has achieved success in treating the HER2+ve subtype of breast cancer, the non-specific action of the HER2 inhibitors has limited the practicality of this approach [78,79,80]. This evidence concerns the gene ERBB2 and breast carcinoma.